Latest Celgene Corp News and Updates
How Vertex’s Revenue and Earnings Surprised in 2Q16
Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.
How Is Novartis’s Cosentyx Positioned after 4Q17?
In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.
A Look at Ionis’s Revenue Streams in the Second Quarter
Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.
Celgene’s Revlimid Expected to Post Strong Revenue in 2017
According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.
Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio
Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.
Must-Read: Amgen’s 3Q15 Earnings and Conference Call
In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.
What to Expect from BioMarin Pharmaceuticals in 2017
In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).
Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16
After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.
Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15
Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.
How Xtandi Fueled Big Pharmaceutical Interest in Medivation
Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.
Third Point Partners ups stake in Amgen
The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”
Celgene Stock Performance in 1Q18
Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.
Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings
Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.
What Were the Top Holdings of Citadel Advisors in Q3?
In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.
Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017
In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.
Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline
After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.
Overview: Highbridge Capital Management’s 2Q14 positions
Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
Behind Celgene’s Blockbuster Revenue Hit in 4Q16
In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.
The George Soros Fund Shares 13F Analysis
On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.
What’s Gilead Sciences’ Valuation?
Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.
How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings
Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.
AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?
AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.
How Much Does Biogen Spend on Research and Development?
Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.
Allergan’s 1Q18 Earnings: Analysts’ Estimates
Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.
How’s Celgene’s Abraxane Positioned after 4Q17?
In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.
Why Sesen Bio Stock Jumped Over 37% this Week
Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.
Gilead Sciences’ Valuation Continues to Lag behind Peers
Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.
What Do Analysts Recommend for AbbVie?
Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.
What Biogen Is Doing that Put It in Good Favor with Analysts
Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.
Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth
On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.
Celgene’s Operating Expenses in 3Q15
In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.
Inside AbbVie’s Analyst Recommendations in 2016
Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”
Celgene Estimates Robust Revenue in 2017
In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.
An Easier Way to Understand the Pharma Industry
In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.
Third Point believes Amgen’s acquisitions should have done more
Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.
Renaissance Technologies: Analyzing Its Q3 13F
At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.
AbbVie Expects Peak Sales of $7 Billion for Imbruvica
AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.
Analyzing Tudor Investment’s Top Holdings
Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.
Amgen and Celgene’s Otezla Deal: Key Highlights
On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.
What’s the Latest on the BMY-Celgene Deal?
Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.
Roche Holdings to Acquire Spark Therapeutics
On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).
ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt
AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.
AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?
On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.
What Analysts Recommend for AbbVie and Celgene This Month
On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.
Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?
Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.
BMY and Celgene to Form a Leading Global BioPharma Company
According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.
Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years
According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.
What to Expect from BMY’s Celgene Acquisition
The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.
Bristol-Myers Squibb to Acquire Celgene
Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.
Taking Stock of bluebird bio’s Performance
In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.
A Look at Abraxane’s Revenue Growth Trajectory in 2018
In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.
A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018
On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.
Inflammation and Immunology: Celgene’s Diversified Research Pipeline
Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.
Why Has AstraZeneca’s Stock Price Increased in 2018?
On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.
How Wall Street Analysts View Merck
On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.
Analysts Expect Incyte to Report Revenue Growth in Third Quarter
Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.
Johnson & Johnson’s Oncology Business Saw Solid Growth in Q3
Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.
Biogen: Analysts’ Recommendations on October 19
For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”
Celgene: Multiple Myeloma Franchise Could Drive Growth
In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.
Celgene’s Financial Position before Its Third-Quarter Earnings
Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.
Cara Therapeutics: Performance and Estimates for Q3
Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.
Allergan’s Stock Performance and Estimates for Q3 2018
Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.
Ionis Pharmaceuticals’ Revenue Stream
Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.
Allergan’s Developments in September
On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.
Here Are the Key Products in Sage’s GABA Receptor Portfolio
Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.
Considering Allergan’s Q2 2018 Revenue Trend
As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.
Analyst Recommendations for Biogen and Its Peers in August
On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.
What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?
In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.
What to Expect from Sarepta’s Second-Quarter Earnings
Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.
What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.
Shire’s Q2 2018 Earnings Beat Analyst Estimates
Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.
Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates
Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.
Merck Witnessed 5% Growth in Q2 2018
Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.
Amgen Beats Estimates, Reports Growth in Q2 2018
Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.
Amgen Announced the Phase 3 Results for ABP 710
On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.
Why Editas Medicine Fell 7.8% on Monday
On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.
How Much Upside Potential Does Celgene Offer?
Of the 30 analysts covering Celgene in May, 15 analysts rated the stock a “buy” or higher, and 14 analysts gave Celgene a “hold” rating.
How Celgene Performed in 1Q18
In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.
18 Earnings Reports We’re Watching Closely Next Week
Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]
Otezla: Shoring Up Celgene’s Top Line
Celgene’s Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in US, Japanese, EU, and other markets.
Gilead Sciences’ Valuation in March 2018
Gilead Sciences surpassed analysts’ estimates and reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17.
Kymriah May Emerge as a Robust Treatment Option in DLBCL Indication
Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.
Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US
The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.
Imbruvica Leads in the Chronic Lymphocytic Leukemia Space
AbbVie (ABBV) expects Imbruvica to contribute ~$3.3 billion in revenue in 2018, including $2.7 billion worth of sales contributions from the US market.
Sanofi Leads the Hemophilia Space on Bioverativ Acquisition
According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.
Exploring Bioverativ’s Business Profile and Market Presence
Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.
Humira Will Remain a Key Growth Driver for AbbVie in 2018
AbbVie (ABBV) expects Humira to report year-over-year (or YoY) growth in its US market sales in the range of 13%–14% in 2018.
GSK Is Focused on Innovative Assets in Oncology Research Pipeline
In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.
Inside Atara Biotherapeutics’ Promising Product Pipeline
Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.
Celgene on the Street: Analysts Recommendations in January
In 1Q17, 2Q17, and 3Q17, Celgene (CELG) generated revenues of $2.96 billion, $3.27 billion, and $3.29 billion, respectively.
Celgene to Acquire Juno Therapeutics
On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.
How Is Novartis’s Cosentyx Positioned for 2018?
In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $410 million, $490 million, and $556 million, respectively.
Novartis’s Crizanlizumab Demonstrates Positive Results in Trials
In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.
Key Updates on Novartis’s Kymriah
In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).
Exploring Ionis’s 3Q17 Quarterly Revenue Trend
Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.
Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications
AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease.
Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017
In its 3Q17 earnings conference call, AbbVie raised its fiscal 2017 adjusted diluted EPS (earnings per share) guidance from $5.44–$5.54 to $5.53–$5.55.
How Increasing Biologic Penetration Could Boost AbbVie’s Revenues
AbbVie (ABBV) is currently focused on advancing the research programs for its late-stage immunology assets, Upadacitinib and Risankizumab.